What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus?

Joint Bone Spine

Volumn 76, Issue 5, 2009, Pages 501-507

  Zhao, Yi ^a   Li, Jing ^b   Li, Xiao xia ^a   Li, Chun ^c   Li, Lin ^a   Li, Zhan guo ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Anti cyclic citrullinated peptide antibodies; Arthritis; Systemic lupus erythematosus

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD SAMPLING; BONE EROSION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CHINA; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PEPTIDES, CYCLIC; REFERENCE VALUES; YOUNG ADULT;

EID: 70449519335     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.11.007     Document Type: Article

References (36)

1. Bukhari M., Harrison B., Lunt M., et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 44 (2001) 1248-1253
2. Cohen M.G., and Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 46 (1987) 853-858
3. Fischman A.S., Abeles M., Zanetti M., et al. The coexistence of rheumatoid arthritis and systemic lupus erythematosus: a case report and review of the literature. J Rheumatol 8 (1981) 405-415
4. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43 (2000) 155-163
5. Suzuki K., Sawada T., Murakami A., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32 (2003) 197-204
6. Zeng X., Ai M., Tian X., et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30 (2003) 1451-1455
7. Kastbom A., Strandberg G., Lindroos A., et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63 (2004) 1085-1089
8. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43 (2000) 1831-1835
9. Bongi S.M., Manetti R., Melchiorre D., et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis: anti-CCP and bone damage in RA. Autoimmunity 37 (2004) 495-501
10. Korendowych E., Owen P., Ravindran J., et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 1056-1060
11. Kasapçopur O., Altun S., Aslan M., et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 63 (2004) 1687-1689
12. Gottenberg J.E., Mignot S., Nicaise-Rolland P., et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 64 (2005) 114-117
13. Mediwake R., Isenberg D.A., Schellekens G.A., et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60 (2001) 67-68
14. Hoffman I.E., Peene I., Cebecauer L., et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 330-332
15. Chan M.T., Owen P., Dunphy J., et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol 35 (2008) 77-83
16. Renaudineau Y., Croquefer S., Jousse S., et al. Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 54 (2006) 2523-2532
17. Purcell S.M., Lieu T.S., Davis B.M., et al. Relationship between circulating anti-Ro/SS-A antibody levels and skin disease activity in subacute cutaneous lupus erythematosus. Br J Dermatol 117 (1987) 277-287
18. Buyon J.P. Neonatal lupus syndromes. Curr Opin Rheumatol 6 (1994) 523-529
19. Tan E., Cohen A., Fries J., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
20. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725 [letter]
21. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
22. van Gaalen F.A., Visser H., and Huizinga T.W. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1510-1512
23. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50 (2004) 380-386
24. Richter Cohen M., Steiner G., Smolen J.S., et al. A. Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol 37 (1998) 421-424
25. Steiner G., Hartmuth K., Skriner K., et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 90 (1992) 1061-1066
26. Hassfeld W., Steiner G., Hartmuth K., et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 32 (1989) 1515-1520
27. Lutteri L., Malaise M., and Chapelle J.P. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 386 (2007) 76-81
28. Luis Caro-Oleas J., Fernández-Suárez A., Reneses Cesteros S., et al. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med 45 (2007) 1396-1401
29. Enriconi Dos Anjos L.M., Pereira I.A., D'orsi E., et al. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28 (2009) 153-158
30. Panush R.S., Edwards N.L., Longley S., et al. 'Rhupus' syndrome. Arch Intern Med 148 (1988) 1633-1636
31. Fernández A., Quintana G., Rondón F., et al. Lupus arthropathy: a case series of patients with rhupus. Clin Rheumatol 25 (2006) 164-167
32. Simón J.A., Granados J., Cabiedes J., et al. Clinical and immunogenetic characterization of Mexican patients with 'rhupus'. Lupus 11 (2002) 287-292
33. Fernández A., Quintana G., Matteson E.L., et al. Lupus arthropathy: historical evolution from deforming arthritis to rhupus. Clin Rheumatol 23 (2004) 523-526
34. Boire G., Ménard H.A., Gendron M., et al. Rheumatoid arthritis: anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster. J Rheumatol 20 (1993) 1654-1660
35. Cavazzana I., Franceschini F., Quinzanini M., et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 24 (2006) 59-64
36. Schneeberger E., Citera G., Heredia M., et al. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 27 (2008) 517-519